Microsoft Word 11.0.5604;UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): May 31, 2005


                           SAFETEK INTERNATIONAL, INC.
                           ---------------------------
             (Exact name of Registrant as specified in its charter)


           Delaware                       33-22175             75-2226896
           ---------                      --------             ----------
(State or other jurisdiction of   (Commission File Number)    (IRS Employer
         incorporation)                                     Identification No.)


                               21 Ahavat Zion St.
                             Tel Aviv, Israel 62153
                    (Address of principal executive offices)

                                 +972-3-5463251
              (Registrant's telephone number, including area code)


                                    ---------
          (Former name or former address, if changed since last report)

<PAGE>

Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On May 31, 2005, Oriens Life Sciences (Israel), Ltd. (the "Subsidiary"), a
wholly owned subsidiary of Safetek International, Inc. (the "Registrant")
entered into an Employment Agreement (the "Employment Agreement") with Shay
Goldstein ("Dr. Goldstein"), who is a director and officer of both the
Subsidiary and the Registrant. Pursuant to such Employment Agreement, Dr.
Goldstein shall serve as the Chief Executive Officer of the Subsidiary,
commencing as of May 1, 2005 and continuing until terminated by either party
thereto. As compensation for his services, Dr. Goldstein shall receive a monthly
salary, which shall be equal to $6,000 per month for the first three months,
$7,500 per month during the fourth through sixth months, and $8,500 per month
thereafter. Dr. Goldstein will also receive various insurance and retirement
benefits. In addition, Dr. Goldstein will receive a bonus of $8,500 if
investments made in the Subsidiary and the Company exceed $4,000,000 in the
aggregate. The Employment Agreement requires Dr. Goldstein to maintain in strict
confidence any confidential information of the Subsidiary and the Registrant and
prohibits Dr. Goldstein from competing with the Subsidiary and soliciting its
employees during his employment and for a period of one year thereafter. Dr.
Goldstein's employment may be terminated by the Company at any time for cause,
without notice. Dr. Goldstein's employment may be terminated either by the
Company or Dr. Goldstein for any reason, upon 30 days' prior notice during the
first year of the employment and 90 days' prior written notice thereafter.

On June 7, 2005, the Subsidiary entered into a Consulting Agreement (the
"Consulting Agreement") with Tamar Tzaban-Nahumov ("Tamar"), who is a director
of the Registrant. Pursuant to the Consulting Agreement, Tamar shall be engaged
by the Subsidiary as a consultant to provide the Subsidiary with advisory
services, concerning such financial matters as shall be reasonably requested by
the Subsidiary from time to time. The term of such engagement commenced as of
May 15, 2005, and will continue until terminated by either party, for any reason
whatsoever, upon 30 days' prior written notice. As compensation for her
services, Tamar will be paid a monthly fee equal to (a) $3,500 for every month
in which Tamar performs services for the Subsidiary for at least 20 weekly
working hours, but no more than 25 weekly working hours; or (b) $5,000 for every
month in which Tamar performs services for the Subsidiary for at least 25 weekly
working hours. The Consulting Agreement requires Tamar to maintain in strict
confidence any confidential information of the Subsidiary and the Registrant and
prohibits Tamar from competing with the Subsidiary and soliciting its employees
during her engagement as a consultant and for a period of one year thereafter.

On June 7, 2005, the Registrant entered into a separate Indemnity Agreement (the
"Indemnity Agreements") with each of Shay Goldstein, who is a director and
officer of the Registrant and the Subsidiary, Tamar Tzaban-Nahumov, who is a
director of the Registrant, and Jean Pierre Elisha Martinez, who is a director
of the Registrant and the Subsidiary. The substantive terms of each Indemnity

<PAGE>

Agreement are identical. Pursuant to such Indemnity Agreements, the Registrant
shall indemnify the indemnitee for all liabilities and damages that may be
incurred by the indemnitee in connection with his or her position as a director
or officer of the Registrant and/or the Subsidiary, as the case may be. Such
indemnity will be effective unless proved that such liabilities arose as a
result of the indemnitee's breach of his or her fiduciary duties, and such
breach involved intentional misconduct, fraud, or a knowing violation of law.

For all the terms of the Employment Agreement, Consulting Agreement, and
Indemnity Agreements, reference is hereby made to such agreements annexed
hereto, respectively, as Exhibit 10.3, 10.4, 10.5, 10.6, and 10.7. All
statements made herein concerning such agreements are qualified by references to
said exhibits.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

      (a)   Financial Information. Not applicable

      (b)   Pro forma financial information. Not applicable

      (c)   Exhibits. The following exhibit is included with this report:

      Exhibit 10.3 Employment Agreement, dated May 31, 2005, between Shay
      Goldstein and Oriens Life Sciences (Israel), Ltd.

      Exhibit 10.4 Consulting Agreement, dated June 7, 2005, between Tamar
      Tzaban Nahumov and Oriens Life Sciences (Israel), Ltd.

      Exhibit 10.5 Indemnity Agreement, dated June 7, 2005 between Shay
      Goldstein and Safetek International, Inc.

      Exhibit 10.6 Indemnity Agreement, dated June 7, 2005 between Tamar
      Tzaban-Nahumov and Safetek International, Inc.

      Exhibit 10.7 Indemnity Agreement, dated June 7, 2005 between Jean Pierre
      Elisha Martinez and Safetek International, Inc.

<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.


                                    SAFETEK INTERNATIONAL, INC.
                                    (Registrant)

                                    By:    /s/ Shay Goldstein
                                           ----------------------------------
                                    Name:  Shay Goldsten,
                                    Title: Chairman, Chief Executive Officer,
Secretary, and Director



Date:  June 9, 2005
{"company-data": {"conformed-name": "SAFETEK INTERNATIONAL INC", "cik": "0000833080", "assigned-sic": "3080", "irs-number": "752226896", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "033-22175", "film-number": "05888665"}, "business-address": {"street1": "5509 11TH AVENUE", "city": "BROOKLYN", "state": "NY", "zip": "11219", "phone": "7025588202"}, "mail-address": {"street1": "5509 11TH AVENUE", "city": "BROOKLYN", "state": "NY", "zip": "11219"}, "former-company": {"former-conformed-name": "THEORETICS INC", "date-changed": "19890718"}}
Microsoft Word 11.0.5604;UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): May 31, 2005

                           SAFETEK INTERNATIONAL, INC.
                           ---------------------------
             (Exact name of Registrant as specified in its charter)

           Delaware                       33-22175             75-2226896
           ---------                      --------             ----------
(State or other jurisdiction of   (Commission File Number)    (IRS Employer
         incorporation)                                     Identification No.)

                               21 Ahavat Zion St.
                             Tel Aviv, Israel 62153
                    (Address of principal executive offices)

                                 +972-3-5463251
              (Registrant's telephone number, including area code)

                                    ---------
          (Former name or former address, if changed since last report)
Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On May 31, 2005, Oriens Life Sciences (Israel), Ltd. (the "Subsidiary"), a
wholly owned subsidiary of Safetek International, Inc. (the "Registrant")
entered into an Employment Agreement (the "Employment Agreement") with Shay
Goldstein ("Dr. Goldstein"), who is a director and officer of both the
Subsidiary and the Registrant. Pursuant to such Employment Agreement, Dr.
Goldstein shall serve as the Chief Executive Officer of the Subsidiary,
commencing as of May 1, 2005 and continuing until terminated by either party
thereto. As compensation for his services, Dr. Goldstein shall receive a monthly
salary, which shall be equal to $6,000 per month for the first three months,
$7,500 per month during the fourth through sixth months, and $8,500 per month
thereafter. Dr. Goldstein will also receive various insurance and retirement
benefits. In addition, Dr. Goldstein will receive a bonus of $8,500 if
investments made in the Subsidiary and the Company exceed $4,000,000 in the
aggregate. The Employment Agreement requires Dr. Goldstein to maintain in strict
confidence any confidential information of the Subsidiary and the Registrant and
prohibits Dr. Goldstein from competing with the Subsidiary and soliciting its
employees during his employment and for a period of one year thereafter. Dr.
Goldstein's employment may be terminated by the Company at any time for cause,
without notice. Dr. Goldstein's employment may be terminated either by the
Company or Dr. Goldstein for any reason, upon 30 days' prior notice during the
first year of the employment and 90 days' prior written notice thereafter.

On June 7, 2005, the Subsidiary entered into a Consulting Agreement (the
"Consulting Agreement") with Tamar Tzaban-Nahumov ("Tamar"), who is a director
of the Registrant. Pursuant to the Consulting Agreement, Tamar shall be engaged
by the Subsidiary as a consultant to provide the Subsidiary with advisory
services, concerning such financial matters as shall be reasonably requested by
the Subsidiary from time to time. The term of such engagement commenced as of
May 15, 2005, and will continue until terminated by either party, for any reason
whatsoever, upon 30 days' prior written notice. As compensation for her
services, Tamar will be paid a monthly fee equal to (a) $3,500 for every month
in which Tamar performs services for the Subsidiary for at least 20 weekly
working hours, but no more than 25 weekly working hours; or (b) $5,000 for every
month in which Tamar performs services for the Subsidiary for at least 25 weekly
working hours. The Consulting Agreement requires Tamar to maintain in strict
confidence any confidential information of the Subsidiary and the Registrant and
prohibits Tamar from competing with the Subsidiary and soliciting its employees
during her engagement as a consultant and for a period of one year thereafter.

On June 7, 2005, the Registrant entered into a separate Indemnity Agreement (the
"Indemnity Agreements") with each of Shay Goldstein, who is a director and
officer of the Registrant and the Subsidiary, Tamar Tzaban-Nahumov, who is a
director of the Registrant, and Jean Pierre Elisha Martinez, who is a director
of the Registrant and the Subsidiary. The substantive terms of each Indemnity
Agreement are identical. Pursuant to such Indemnity Agreements, the Registrant
shall indemnify the indemnitee for all liabilities and damages that may be
incurred by the indemnitee in connection with his or her position as a director
or officer of the Registrant and/or the Subsidiary, as the case may be. Such
indemnity will be effective unless proved that such liabilities arose as a
result of the indemnitee's breach of his or her fiduciary duties, and such
breach involved intentional misconduct, fraud, or a knowing violation of law.

For all the terms of the Employment Agreement, Consulting Agreement, and
Indemnity Agreements, reference is hereby made to such agreements annexed
hereto, respectively, as Exhibit 10.3, 10.4, 10.5, 10.6, and 10.7. All
statements made herein concerning such agreements are qualified by references to
said exhibits.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

      (a)   Financial Information. Not applicable

      (b)   Pro forma financial information. Not applicable

      (c)   Exhibits. The following exhibit is included with this report:

      Exhibit 10.3 Employment Agreement, dated May 31, 2005, between Shay
      Goldstein and Oriens Life Sciences (Israel), Ltd.

      Exhibit 10.4 Consulting Agreement, dated June 7, 2005, between Tamar
      Tzaban Nahumov and Oriens Life Sciences (Israel), Ltd.

      Exhibit 10.5 Indemnity Agreement, dated June 7, 2005 between Shay
      Goldstein and Safetek International, Inc.

      Exhibit 10.6 Indemnity Agreement, dated June 7, 2005 between Tamar
      Tzaban-Nahumov and Safetek International, Inc.

      Exhibit 10.7 Indemnity Agreement, dated June 7, 2005 between Jean Pierre
      Elisha Martinez and Safetek International, Inc.
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

                                    SAFETEK INTERNATIONAL, INC.
                                    (Registrant)

                                    By:    /s/ Shay Goldstein
                                           ----------------------------------
                                    Name:  Shay Goldsten,
                                    Title: Chairman, Chief Executive Officer,
Secretary, and Director

Date:  June 9, 2005